Company profile: Synchroneuron
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies under development for tardive dyskinesia and other related movement disorders, including lead candidate SNC-102, a sustained-release formulation of acamprosate calcium in phase 2 trials for tardive dyskinesia and Tourette syndrome.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Synchroneuron
NeuroSigma
HQ: United States
Website
- Description: Provider of trigeminal nerve stimulation (TNS) medical devices and therapies for neurologic and psychiatric disorders. The company commercializes its TNS technology with a pipeline targeting epilepsy, depression, ADHD, and PTSD. Products include the Monarch eTNS System, a non-drug treatment device for pediatric ADHD used during sleep under caregiver supervision.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeuroSigma company profile →
BioDelivery Sciences International
HQ: United States
Website
- Description: Provider of pharmaceutical solutions focused on pain management and addiction medicine, leveraging proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology to develop and commercialize new applications of proven therapies independently or through partnerships.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioDelivery Sciences International company profile →
PaxMedica
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies addressing neurodevelopmental disorders, including PAX-101 for early-stage East African Human African Trypanosomiasis and PAX-101 under development for Autism Spectrum Disorder. Conducts clinical trials evaluating suramin in ASD and collaborates on translational research to support research leading to FDA-approved treatments for autism comorbidities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PaxMedica company profile →
Cognito Therapeutics
HQ: United States
Website
- Description: Provider of non-invasive gamma wave therapy that evokes brain gamma activity via visual and auditory stimulation to slow cognitive and functional decline in Alzheimer’s; personalized intensity guided by EEG. Runs the HOPE pivotal study and Phase 2 OVERTURE showing preserved cognition, daily function, and brain volume. Holds FDA Breakthrough Device Designation; developing disease-modifying treatments for CNS illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cognito Therapeutics company profile →
Premier Biotech
HQ: United States
Website
- Description: Provider of drug testing diagnostic devices and laboratory services, including drugs of abuse testing delivering accurate results in under 10 minutes with observed collection to prevent adulteration. Offers the OT-Scan app for capturing and reporting drug screen results with automated test interpretation, secure data transmission, and in-app confirmation testing ordering.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Premier Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Synchroneuron
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Synchroneuron
2.2 - Growth funds investing in similar companies to Synchroneuron
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Synchroneuron
4.2 - Public trading comparable groups for Synchroneuron
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →